CTOs on the Move

uniPHARM Wholesale Drugs

www.unipharm.com

 
uniPHARM Wholesale Drugs Ltd. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.unipharm.com
  • 2051 Van Dyke Pl
    Richmond, BC CAN V6V 1X6
  • Phone: 604.270.9745

Executives

Name Title Contact Details

Similar Companies

Integrated BioPharma

Integrated BioPharma is a Hillside, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celera Corporation

Celera Corporation (Celera) is a healthcare business delivering personalized disease management through a combination of products and services. The Company operates in three segments: a clinical laboratory testing service business (Lab Services), a

Accord Healthcare

Accord Healthcare is a global provider of generic and specialty pharmaceuticals. Our focus on a rapidly expanding portfolio of affordable generic…

Spectrum Pharmaceuticals

Spectrum`s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Gemini Therapeutics

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.